Editorial
doi: 10.1056/NEJMe1610510.
Engineering Reversal - Finding an Antidote for Direct Oral Anticoagulants
Affiliations
- PMID: 27653570
- DOI: 10.1056/NEJMe1610510
Item in Clipboard
Editorial
Engineering Reversal - Finding an Antidote for Direct Oral Anticoagulants
N Engl J Med.
.
No abstract available
Comment in
-
Andexanet Alfa for Factor Xa Inhibitor Reversal.N Engl J Med. 2016 Dec 22;375(25):2499. doi: 10.1056/NEJMc1613270. N Engl J Med. 2016. PMID: 28002712 No abstract available.
-
Andexanet Alfa for Factor Xa Inhibitor Reversal.N Engl J Med. 2016 Dec 22;375(25):2500. doi: 10.1056/NEJMc1613270. N Engl J Med. 2016. PMID: 28009496 No abstract available.
Comment on
-
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.N Engl J Med. 2016 Sep 22;375(12):1131-41. doi: 10.1056/NEJMoa1607887. Epub 2016 Aug 30. N Engl J Med. 2016. PMID: 27573206 Free PMC article. Clinical Trial.
Similar articles
-
Oral anticoagulants and status of antidotes for the reversal of bleeding risk.Clin Appl Thromb Hemost. 2015 Mar;21(2):105-14. doi: 10.1177/1076029614545211. Epub 2014 Aug 12. Clin Appl Thromb Hemost. 2015. PMID: 25115762 Review.
-
Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors.Expert Rev Cardiovasc Ther. 2017 Apr;15(4):237-245. doi: 10.1080/14779072.2017.1305889. Epub 2017 Mar 22. Expert Rev Cardiovasc Ther. 2017. PMID: 28282497 Review.
-
Management of Elective Surgery and Emergent Bleeding with Direct Oral Anticoagulants.Curr Cardiol Rep. 2017 Oct 24;19(12):124. doi: 10.1007/s11886-017-0930-2. Curr Cardiol Rep. 2017. PMID: 29064044 Review.
-
Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants.J Thromb Thrombolysis. 2016 Feb;41(2):248-52. doi: 10.1007/s11239-015-1288-1. J Thromb Thrombolysis. 2016. PMID: 26449414 Review.
-
Pharmacologic Reversal of Direct Oral Anticoagulants.Crit Care Nurs Q. 2018 Apr/Jun;41(2):121-128. doi: 10.1097/CNQ.0000000000000193. Crit Care Nurs Q. 2018. PMID: 29494368
Cited by
-
The anticoagulant effects of milvexian, a novel small molecule factor XIa inhibitor, are neutralized by activated prothrombin complex concentrates and recombinant factor VIIa in human plasma and whole blood in vitro.Res Pract Thromb Haemost. 2024 Oct 23;8(8):102600. doi: 10.1016/j.rpth.2024.102600. eCollection 2024 Nov. Res Pract Thromb Haemost. 2024. PMID: 39687926 Free PMC article.
-
Spontaneous splenic rupture due to rivaroxaban.BMJ Case Rep. 2018 Mar 5;2018:bcr2017223237. doi: 10.1136/bcr-2017-223237. BMJ Case Rep. 2018. PMID: 29507024 Free PMC article.
-
Reversing factor Xa inhibitors - clinical utility of andexanet alfa.J Blood Med. 2017 Sep 13;8:141-149. doi: 10.2147/JBM.S121550. eCollection 2017. J Blood Med. 2017. PMID: 28979172 Free PMC article. Review.
-
[Comment on: Andexanet alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.].Anaesthesist. 2016 Dec;65(12):940-942. doi: 10.1007/s00101-016-0240-x. Anaesthesist. 2016. PMID: 27778054 German. No abstract available.
-
Management of Factor Xa inhibitor-associated life-threatening major hemorrhage: A retrospective multi-center analysis.Am J Emerg Med. 2018 Mar;36(3):396-402. doi: 10.1016/j.ajem.2017.08.042. Epub 2017 Aug 19. Am J Emerg Med. 2018. PMID: 28843518 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
